MMA Embolization for Refractory Chronic Migraine
Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
- Migraine Disorders
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Enrolment target
- 70
- Started
- 23 April 2025
- Main results due
- 25 December 2026
- Study sites
- 8
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 65 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Participant Inclusion Criteria, Candidates for this study must meet ALL the following inclusion criteria: 1. Patient is between 18 and 65 years of age (inclusive) at the time of consent 2. Age of onset of Chronic Migraine \<= 64 years 3. Age of onset of migraine diagnosis \< 50 years 4. Patient has a current diagnosis of refractory migraine 5. Patient has a current diagnosis of Chronic migraine Participant Exclusion Criteria, Candidates will be excluded from participation if ANY of the following apply: 1. Patients with a history for the last 2 years of other primary headache types, or secondary headache types except medication overuse headache 2. Patients with diagnosis of hemiplegic migraine or migrainous infarct 3. Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc 4. Women who are pregnant, lactating, or who are of childbearing age 5. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Participants in observational, natural history, and/or epidemiological studies not involving intervention are eligible. Sponsor approval is required
What this study is about
In the sponsor’s own words, from the registry.
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Study sites(8)
John Muir Physician Network Clin. Research Center
Walnut Creek, California, United States
Recruiting
Hartford Hospital
Hartford, Connecticut, United States
Recruiting
University of Buffalo Medical Center
Buffalo, New York, United States
Recruiting
Mount Sinai
New York, New York, United States
Recruiting
Stony Brook University Medical Center
Stony Brook, New York, United States
Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Recruiting
Semmes Murphey Foundation
Memphis, Tennessee, United States
Recruiting
West Virginia University
Morgantown, West Virginia, United States
Recruiting
Showing 8 of 8 sites. 8 of the 8 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06735833. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me